On Dec. 12, the Cambridge, Mass.-based company said several leaders, including Chief Medical Officer Baisong Mei, MD, PhD, will depart during this transition.
Editas said the restructuring will “extend its cash runway” into the second quarter of 2027 and “accelerate its intent to achieve in vivo human proof of concept in approximately two years.”
The company also reported preclinical achievements in liver and blood stem cell research.
